<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dialogues Clin Neurosci</journal-id><journal-id journal-id-type="pmc">Dialogues Clin Neurosci</journal-id><journal-title-group><journal-title>Dialogues in Clinical Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1294-8322</issn><issn pub-type="epub">1958-5969</issn><publisher><publisher-name>Les Laboratoires Servier</publisher-name><publisher-loc>France</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22033776</article-id><article-id pub-id-type="pmc">3181667</article-id><article-categories><subj-group subj-group-type="heading"><subject>Basic Research</subject></subj-group></article-categories><title-group><article-title>The role of substance P in depression: therapeutic implications</article-title><trans-title-group xml:lang="es"><trans-title>El papel de la sustancia P en la depresi&#x000f3;n y implicaciones terap&#x000e9;uticas</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title>R&#x000f4;le de la substance P dans la d&#x000e9;pression: implications th&#x000e9;rapeutiques</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schwarz</surname><given-names>Markus J.</given-names></name><degrees>MD</degrees><aff>Department of Neurochemistry, Psychiatric Hospital, University of Munich, Germany</aff></contrib><contrib contrib-type="author"><name><surname>Ackenheil</surname><given-names>Manfred</given-names></name><degrees>MD</degrees><xref ref-type="corresp" rid="COR2">*</xref><aff>Department of Neurochemistry, Psychiatric Hospital, University of Munich, Germany</aff></contrib></contrib-group><author-notes><corresp id="COR2"><label>*</label>
E-mail: <email>ac@psy.med.uni-muenchen.de</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>3</month><year>2002</year></pub-date><!--Fake ppub date generated  by PMC from publisher pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>3</month><year>2002</year></pub-date><volume>4</volume><issue>1</issue><fpage>21</fpage><lpage>29</lpage><permissions><copyright-statement>Copyright: &#x000a9; 2002 LLS</copyright-statement><copyright-year>2002</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Substance P (for &#x0201c;powder&#x0201d;), identified as a gut tachykinin in 1931 and involved in the control of multiple other autonomic functions, notably pain transmission, is the focus of intense fundamental and clinical psychiatric research as a central neurotransmitter, neuromodulator, and immunomodulator, along with sister neurokinins A and B (NKA and NKB), discovered in 1984. Substance P is widely distributed throughout the central nervous system, where if is often colocalized with serotonin, norepinephrine, and dopamine. Many neurokinin (NK) receptor antagonists and agonists have been synthesized and some clinically tested. A double-blind study of MK869, a selective NK1 receptor antagonist that blocks the action of substance P, showed significant activity versus placebo and fewer sexual side effects than paroxetine in outpatients with major depression and moderate anxiety. Substance P, which is degraded by the angiotensin-converting enzyme (ACE), may mediate modulation of therapeutic outcome in affective disorders by functional polymorphism within the ACE gene: the D allele is associated with higher ACE levels and increased neuropeptide degradation, with the result that patients with major depression who carry the D allele have lower depression scores and shorter hospitalization. ACE polymorphism genotypinq might thus identify those patients with major depression likely to benefit from NK1 receptor antagonist therapy.</p></abstract><trans-abstract xml:lang="es"><p>La sustancia P (por &#x0201c;polvo&#x0201d;), identificada como una taquiquinina intestinal en 1331 e involucrada en el control de otras m&#x000fa;ltiples funciones auton&#x000f3;micas, especialmente en la transmisi&#x000f3;n del dolor, es el foco de una intensa investigaci&#x000f3;n b&#x000e1;sica y en psiquiatr&#x000ed;a clinica como un neurotransmisor, neuromodulador e inmunomodulador central, junto a las neuroquininas hermanas A y B (NKA y NKB), descubiertas en 1984. La sustancia P se disiribuye extensamente a trav&#x000e9;s del sistema nervioso central, donde a menudo se co-localiza con serotonina, noradrenalina y dopamina. Se han sintetizado muchos agonistas y antagonistas de receptores de neuroquininas (NK) y algunos de ellos se han evaluado cl&#x000ed;nicamente. Un estudio doble ciego de MK869, un antagonista selectivo del receptor NK1 que bloquea la acci&#x000f3;n de la sustancia P demostr&#x000f3; actividad significativa al compararlo contra el placebo y menos efectos sexuales colaterales que la paroxetina en pacientes ambulatorios con &#x000f3;n mayor y ansiedad moderada. La sustancia P, que es degradada por la enzima convertidora de angiotensina (ECA), puede mediar la modulaci&#x000f3;n de la evoluci&#x000f3;n terap&#x000e9;utica de los trastornos afectivos a trav&#x000e9;s del polimorfismo funcional dentro del gen de la ECA: el alelo D se asocia con nivel&#x000e9;s m&#x000e1;s elevados de ECA y un aumento en la degradati&#x000f3;n del neurop&#x000e9;ptido. Esto se traduce en que pacientes con depresi&#x000f3;n mayor que poseen el alelo D tienen puntajes menores de depresi&#x000f3;n y hospitalizaciones m&#x000e1;s breves. La determinaci&#x000f3;n gen&#x000e9;tica del polimorfismo de la ECA podrfa as&#x000ed; identificar a aquellos pacientes con depresi&#x000f3;n mayor que probablemente se beneficiar&#x000ed;an con una terapia con antagonistas del receptor NK1.</p></trans-abstract><trans-abstract xml:lang="fr"><p>La substance P (pour poudre), identifi&#x000e9;e comme une tachykinine intestinale en 1931 et impliqu&#x000e9;e dans le contr&#x000f4;le de nombreuses autres fonctions autonomes, en particulier la transmission de la douleur, a suscit&#x000e9; d'intenses recherches cliniques et fondamentales en psychiatrie en tant que neurotransmetteur, neuromodulateur et immunomodulateur central, parall&#x000e8;lement aux neurokinines surs A et B (NKA, NKB), d&#x000e9;couvertes en 1984. La substance P est largement r&#x000e9;pandue dans le syst&#x000e8;me nerveux central o&#x000f9; elle coexiste souvent avec la s&#x000e9;rotonine, la noradrenaline et la dopamine. De nombreux agonistes et antagonistes des r&#x000e9;cepteurs aux neurokinines (NK) ont &#x000e9;t&#x000e9; synth&#x000e9;tis&#x000e9;s et pour certains cliniquement test&#x000e9;s. Une &#x000e9;tude en double aveugle du MK869, un antagoniste s&#x000e9;lectif du r&#x000e9;cepteur NK1 qui bloque l'action de la substance P, a montr&#x000e9; une activit&#x000e9; significative vs placebo et moins d'effets secondaires d'ordre sexuel que la paroxetine chez les patients ambulatoires souffrant d'une d&#x000e9;pression s&#x000e9;v&#x000e8;re et d'une anxi&#x000e9;t&#x000e9; mod&#x000e9;r&#x000e9;e. La substance P, qui est d&#x000e9;grad&#x000e9;e par l'inhibiteur l'enzyme de conversion de l'angiotensine (IEC), pourrait m&#x000e9;dier la modulation de l'&#x000e9;volution th&#x000e9;rapeutique des troubles affectifs par un polymorphisme fonctionnel au sein du g&#x000e8;ne de I'IEC: l'all&#x000e8;le D est associ&#x000e9; &#x000e0; des concentrations plus &#x000e9;lev&#x000e9;es d'IEC et une augmentation de la d&#x000e9;gradation des neuropeptides; par cons&#x000e9;quent les patients souffrant d'une d&#x000e9;pression s&#x000e9;v&#x000e8;re et porteurs de l'allele D pr&#x000e9;sentent des scores de d&#x000e9;pression plus faibles et des hospitalisations plus courtes. Le g&#x000e9;notypage du polymorphisme des IEC pourrait ainsi permettre d'identifier les patients ayant une d&#x000e9;pression s&#x000e9;v&#x000e8;re susceptibles de b&#x000e9;n&#x000e9;ficier au mieux d'un traitement par antagonistes des r&#x000e9;cepteurs aux NK1.</p></trans-abstract><kwd-group><kwd><italic>antidepressant drug</italic></kwd><kwd><italic>anxiolytic drug</italic></kwd><kwd><italic>neuropeptide</italic></kwd><kwd><italic>NK1 receptor antagonist</italic></kwd><kwd><italic>substance P</italic></kwd><kwd><italic>tachykinin</italic></kwd></kwd-group></article-meta></front><body><p>In the 1960s, the first tricyclic antidepressant drugs were found to act by blocking the reuptake of the classical neurotransmitters serotonin (5-hydroxytryptamine [5-HT]) and norepinephrine (NE).<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Since then, these two monoamine neurotransmitters have been the focus of antidepressant drug research and the most common pathophysiological concepts of major depression are based on this profile of antidepressant action. Increasing knowledge has indicated that the modulation of monoamines is not the only mechanism for antidepressant actions. Neuropeptides, which are colocalized with monoamines, could also be involved in the pathophysiology of depression. Substance P (SP), which was first detected 70 years ago, came into play in recent years. In 1998, there was an exciting report in the journal <italic>Science</italic> by Kramer et al showing the antidepressant activity of an SP receptor antagonist.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> In the following, we will give a comprehensive overview of the nature of SP, the neuropeptide family it belongs to, and current data regarding the activity of SP receptor antagonists as psychotropic drugs.</p><sec><title>Substance P and the tachykinin family</title><p>SP was the first known neuropeptide. Von Euler and Gaddum isolated SP from extracts of intestine and from brain as one of many substances. As it was in the powdered form, they named it substance P. In the first experiments, SP stimulated contractions of rabbit-ileum in an atropinc-resistant manner. This first report on SP was published in 1931. <sup><xref ref-type="bibr" rid="ref3">3</xref></sup> In 1953, SP was recognized as a sensory neurotransmitter by Lembeck et al.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> It was more than 10 years later that SP was isolated from bovine hypothalamus and sequenced by Susan Leeman and colleagues, culminating her efforts to identify a tissue component that stimulates salivation in rats.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Another 10 years later, the other two mammalian tachykinins were discovered: the cationic peptide neurokinin A (NKA, formerly named substance K) and the anionic peptide neurokinin B(NKB).<sup><xref ref-type="bibr" rid="ref6">6</xref>-<xref ref-type="bibr" rid="ref8">8</xref></sup>
</p><p>The tachykinins (tachys = swift) evoke a sharp contraction of the smooth muscle of the gut.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> These tachykinins are involved in multiple physiological processes, as demonstrated by their widespread distribution. In the periphery, they function as potential regulators of blood flow, vascular permeability, salivation, gastrointestinal motility, intestinal secretion, micturition, and leukocyte activity. Moreover, they act as pain transmitters from the periphery. In the central nervous system (CNS), tachykinins act as neurotransmitters and neuromodulators.</p></sec><sec><title>Tachykinin genes and synthesis</title><p>There are two genes encoding for the synthesis of the three tachykinins SP, NKA, and NKB: the preprotachykinin I <italic>(PPTI)</italic> gene encodes for SP and NKA, while the <italic>PPTII</italic> gene encodes for NKB.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Through alternative splicing, the <italic>PPTI</italic> gene can express four different forms (&#x003b1; &#x003b2;, &#x003b3;, and &#x003b4;) of mRNA. All of these forms are precursors of substance P, but only the &#x003b2; and &#x003b3; forms also encode for the synthesis of NKA and its elongated forms neuropeptide K and neuropeptide &#x003b3;.<sup><xref ref-type="bibr" rid="ref11">11</xref>-<xref ref-type="bibr" rid="ref13">13</xref></sup> Translation of the mRNA generates the so-called grandfather peptide, the prepropeptide. The enzymatic cleavage to the &#x0201c;paternal&#x0201d; propeptide is done inside the endoplasmic reticulum. The last step in generating the active peptide is carried out by converting enzymes in cytoplasmic vesicles. Once the neuropeptides have been released, they are inactivated by catabolic peptidases. The tachykinins are degraded by multiple peptidases in the tissue including the angiotensin-converting enzyme (ACE).<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> There is no reuptake mechanism, as known for the monoamine neurotransmitters.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup>
</p></sec><sec><title>Anatomic distribution of tachykinins within the CNS</title><p>SP is widely distributed throughout the CNS and the myenteric and submucous nerve plexuses of the gut. In the brain, SP is found in the midbrain periaquacductal gray, nucleus raphe magnus, and nucleus reticularis gigantocellularis pars a, which are important structures in the endogenous pain control system.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Large numbers of SP-containing neurons have been found in the human posterior hypothalamus and basal forebrain, indicating an involvement of SP in hypothalamic functions such as sexual behavior or pituitary hormone release.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> SP is also found in the basal ganglia, nucleus accumbens, and - in lower levels - in the cerebral cortex.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Moreover, there is evidence that SP interacts with dopaminergic neurons of nigrostriatal, limbic, and forebrain nuclei.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> NKB neurons are present in the anterior hypothalamus and the basal forebrain, indicating a complementary distribution from SP neurons.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> All three tachykinins are represented in the corpus striatum.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup>
</p></sec><sec><title>Colocalization of substance P with other neurotransmitters in the brain</title><p>In the human brain, 5-HT and SP coexist in a substantial proportion of the cell population of the dorsal raphe nucleus, the current target for antidepressant drug treatment.<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup> Almost 50% of the serotonergic neurons in the dorsal raphe nucleus, projecting to the forebrain, and 25% of the serotonergic neurons in the median raphe nucleus express SP mRNA.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> SP and 5-HT are colocalized in cat ventral medullary neurons<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> and in serotonergic neuronal afferents to the hypoglossal nucleus of the rat.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Moreover, SP is coexpressed with the serotonin receptor subtypes 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, and 5-HT<sub>6</sub> in rat striatum.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> It is remarkable that the expression of SP in the striatum, substantia nigra, and amygdala is reduced after chronic treatment with the antidepressant drugs imipramine, desipramine, clomipramine, amoxapine, and mianserin. Imipramine and desipramine also reduce the amount of SP in the hippocampus, while its reduction in the septum is only induced by mianserin.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup>
</p><p>The colocalization of SP and NE is demonstrated by the existence of SP-containing axon terminals in the locus cerulcus.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> Direct application of SP to the locus ceruleus has an excitatory effect via the neurokinin NK1 receptor.<sup><xref ref-type="bibr" rid="ref29">29</xref>-<xref ref-type="bibr" rid="ref31">31</xref></sup>
</p><p>SP is also colocalized with dopaminergic neurons in the nucleus accumbens.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> SP is under the stimulatory control of dopaminergic neurons, projecting to the substantia nigra pars compacta and to the internal segment of the globus pallidus.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Blockade of dopaminergic transmission by reserpine decreases the levels of SP mRNA, since it is under the stimulatory control of dopamine.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> Chronic treatment with amphetamine was found to be without effect on dopamine receptor levels in the striatum, but markedly increased the SP mRNA levels.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> Some studies suggest that the pain-suppression system involving the activation of mesolimbic dopaminergic neurons is naturally triggered by exposure to stress, through the endogenous release of opioids and SP in the midbrain.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup>
</p><p>SP is also coexpressed with a wide variety of other neuropeptides and neurotransmitters, and even with neuronal nitric oxide synthase.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup>
</p></sec><sec><title>Neurokinin receptors</title><p>Three distinct neurokinin receptors are known: NK1, NK2, and NK3. SP is the most potent tachykinin for the NK1 receptor, whereas NKA exhibits the highest affinity for the NK2 receptor and NKB for the NK3 receptor.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> Recently, the NK4 receptor, which was initially claimed to be an atypical opioid receptor, was shown to respond potently to NKB in the rat,<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> but its detection in human tissue has not been possible to date.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> However, it must be pointed out that all mammalian tachykinins have limited selectivity for a particular neurokinin receptor.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> This is due to the common C-terminal amino acid sequence, which is essential for the biological activity of the tachykinins.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup>
</p><p>The neurokinin receptors are G-protein-coupled receptors with the characteristic seven-membrane-spanning domains.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> In general, several mechanisms prevent the uncontrolled stimulation of cells by neurotransmitters that interact with G-protein-coupled receptors: (i) removal of the agonist from the extracellular fluid by degradation or reuptake (the latter is not relevant to the tachykinins, as stated above); (ii) desensitization of the receptor by uncoupling from the G-proteins to terminate the signal transduction cascade; and (iii) endocytosis of the agonist-stimulated receptor, depleting the plasma membrane of high-affinity receptors.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> The NK1 receptor appears to be desensitized by phosphorylation, independently of receptor internalization, while resensitization requires endocytosis, recycling, and dephosphorylation.<sup><xref ref-type="bibr" rid="ref43">43</xref>-<xref ref-type="bibr" rid="ref44">44</xref></sup> The prompt tachyphylaxis of the NK1 receptor after exposure to the agonist is, however, linked to the rapid receptor internalization.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup>
</p></sec><sec><title>Anatomic distribution of neurokinin receptors within the CNS</title><p>A wide variety of brain regions express the NK1 receptor. Notably, the raphe nuclei, locus ceruleus, striatum, the nucleus accumbens, the hippocampus, the lateral nucleus of the hypothalamus, the habenula, the interpeduncular nucleus, the nucleus of the tractus solitarius, and the substantia nigra are all rich in NK1 receptors.<sup><xref ref-type="bibr" rid="ref46">46</xref>-<xref ref-type="bibr" rid="ref48">48</xref></sup> Thus, there is a remarkable mismatch between SP-containing brain regions and NK1 receptor-expressing brain regions, which may be due to the aforementioned limited selectivity of the tachykinins. NK2 receptors are sparsely distributed in the CNS. They can be found in low amounts in various regions, such as the striatum. The third type of neurokinin receptor, the NK3 receptor, is strikingly prevalent in midcortical laminae throughout the cortex.</p><p>The patterns of expression are therefore very different between the NK1, NK2, and NK3 receptors. NK4 receptor mRNA is widely expressed in neurons in the rat CNS, including cerebral cortex, hippocampus, and hypothalamus.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> The NK1 receptor is also coexpressed with nitric oxide synthase in striatal interneurons in the rat.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> In the spinal cord, NK1 receptors are localized on second-order sensory neurons, receiving nociceptive inputs. The NK1 receptor signal induces a slowly developing sustained depolarization, while the fast input to secondorder sensory neurons is mediated by the excitatory amino acid glutamate through the N-methyl-D-aspartate (NMDA) receptor.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup>
</p></sec><sec><title>Specific actions of the neurokinin receptors</title><p>Elliott and Iversen described the diverse effects of SP after intracerebroventricular (ICV) administration or direct application into the ventral tegmental area of the mesencephalon of rat brain, which caused increased locomotor activity, grooming behavior, and wet dog shakes.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> Repetitive hind paw tapping was also shown to result from activation of central NK1 receptors in gerbils.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> SP locally injected into the caudal pontine reticular nucleus dose-dependently increases the amplitude of the acoustic startle response in rats.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup>
</p><p>Not only simple movements are induced by SP. Even complex behavior in animal models of anxiety and depression can be modulated by NK receptor activation. TCV infusion of the SP analogue, dimethyl-C7, was found to produce aversion in a place-conditioning paradigm.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> Moreover, ICV administration of SP, NKA, and NK1- and NK2-selective agonists produces an anxiogenic effect in the plus-maze test, the mouse model for anxiety behavior.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> In contrast, the synthetic NK3 agonist senktide has an anxiolytic effect.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> This again demonstrates the differential role of the three NK receptors. However, the complexity of the tachykinin system is also represented by differential effects within one NK receptor subtype, as the same receptor can exert contrary effects upon stimulation in different brain regions. One example is the anxiogenic effect of SP microinjection into the rat periaqueductal gray,<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> whereas injection into the nucleus basalis produces an anxiolytic effect.<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> Maternal separation of guinea-pig pups was shown to cause internalization of the NK1 receptors in the baso lateral nucleus of the amygdala, suggesting the binding of SP to its receptor as a response to separation stress.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> In contrast, administration of the NK1 receptor agonist GR73632 induced pronounced long-lasting audible vocalizations, that could be attenuated by pre treatment with the antidepressant drug imipramine.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> To demonstrate the direct relationship between NK1 receptors and anxious behavior, the gene coding for the NK1 receptor was manipulated by deleting the first two transmembrane domains of the receptor molecule. This genetic disruption of the NK1 receptor markedly reduced anxiety-related behavior in the elevated plusmaze, novelty-suppressed feeding, and maternal separation paradigms.<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> However, knock-out mice that totally lacked the NK1 receptor did not exert changed anxietyrelated behavior in the open field test, but were markedly less aggressive than NK(+/+) mice in the resident intruder test of aggression.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> Consistent with these data, SP has been shown to evoke defensive rage in cats through an amygdalo-hypothalamic pathway.<sup><xref ref-type="bibr" rid="ref61">61</xref></sup> Systemic or intrahypothalamic infusion of the NK1 receptor antagonist CP96345 blocked this defensive rage<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> in a similar manner to tricyclic antidepressants.<sup><xref ref-type="bibr" rid="ref63">63</xref></sup>
</p><p>Besides its role in modulating behavior, SP also exerts an important immunomodulating role within the CNS. Local administration of SP increases the interferon -&#x003b3; (IFN-&#x003b3;)-induced upregulation of antigen-presenting major histocompatibility complex (M'HC) molecules in the brainstem, while administration of an NK1 receptor antagonist has the opposite effect.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> Moreover, SP has the potency to influence the so-called T helper 1/ T helper 2 (Th1/Th2) balance in the peripheral immune system, leading to the breakdown of the commitment to a particular T helper cell type.<sup><xref ref-type="bibr" rid="ref65">65</xref></sup> TTiis is most interesting, as a predominance of the Th1-like, IFN-&#x003b3;-related immune response was proposed in major depression.<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> In summary, the immunomodulatory potency of SP may be a relevant component in the pathophysiology of major depression.</p></sec><sec><title>Neurokinin receptor antagonists</title><p>The first peptidergic NK1 receptor antagonists were synthesized in the early 1980s as useful tools for the investigation of the endogenous NK1 ligands.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> Ten years later, Snider and colleagues established the first nonpeptide NK1 receptor antagonist.<sup><xref ref-type="bibr" rid="ref68">68</xref></sup> It was the first step in the race for a pharmacological compound to antagonize the SP signal. It was only 2 years later that the binding epitopes of SP and the new antagonist were detected<sup><xref ref-type="bibr" rid="ref69">69</xref></sup>: the tachykinin binds to the extracellular loops of the receptor, while the nonpeptide antagonists bind more deeply in the transmembrane segments of the receptor molecule. In the meantime, a great variety of nonpeptide antagonists for the NK1, NK2, and NK3 receptors have become available.</p></sec><sec><title>Basic pharmacological studies on neurokinin receptor antagonists</title><p>The important modulating and enhancing role of SP in nociception led to the idea of introducing NK1 receptor antagonists as antinociceptive drugs. A lot of effort was made toward the development of NK1 receptor antagonists for the treatment of pain. Although NK1 receptor antagonists appeared to act synergistically to inhibit NMDA receptors on second-order sensory neurons, they exhibited only weak potency in acute pain.<sup><xref ref-type="bibr" rid="ref70">70</xref></sup> However, antinociceptive efficacy could be observed in nociceptive models of chronic pain. This may be relevant to the treatment of the fibromyalgia syndrome (FM), a syndrome, characterized by chronic widespread pain and depression-like symptoms. Serum and cerebrospinal fluid (CSF) levels of SP are increased in FM, suggesting its probable role in the pathophysiology of FM.<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> We were able to demonstrate a relationship between SP levels and intensity of pain perception in FM patients.<sup><xref ref-type="bibr" rid="ref72">72</xref></sup> Thus, the therapeutic use of NK1 receptor antagonists in FM may be a successful treatment strategy in FM, although they have failed to show antinociceptive efficacy in other chronic pain syndromes like peripheral neuropathy, osteoarthritis, or migraine.<sup><xref ref-type="bibr" rid="ref73">73</xref></sup>
</p><p>Since central administration of SP was shown to induce depression-like and anxious behavior (see above), the NK1 receptor antagonists were tested in several animal models of depression and anxiety. Vocalization evoked in guinea-pig pups or neonatal mice by transient maternal separation could be attenuated by systemic administration of several NK1 receptor antagonists, such as CP99994, L760735, or L733060.<sup><xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref74">74</xref></sup> This effect was comparable to that of clinically used antidepressants (phenelzine, imipramine, fluoxetine) and anxiolytics (diazepam, buspirone). The dose-dependent antidepres sant-like effect of another NK1 receptor antagonist, NKP608, was demonstrated in the chronic mild stress model of depression in rats, where the magnitude of the effect was similar to antidepressants in clinical use, but with a faster onset of action.<sup><xref ref-type="bibr" rid="ref75">75</xref></sup> The same NK1 receptor antagonist also exerted anxiolytic efficacy in rat social interaction tests.<sup><xref ref-type="bibr" rid="ref76">76</xref></sup> As shown by microinjection experiments of NK1 receptor antagonists, the amygdala appears to be one of the sites of action.<sup><xref ref-type="bibr" rid="ref77">77</xref></sup>
</p><p>More evidence for the antidepressant activity of NK1 receptor antagonists is given by their modulation of the serotonergic and norepinephrinergic systems. Systemic administration of an NK1 receptor antagonist enhances the firing rate of the locus ceruleus in response to stress.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> Recently, the activating effect of sustained NK1 receptor blockade on postsynaptic 5-HT<sub>1a</sub> autoreceptors was shown.<sup><xref ref-type="bibr" rid="ref78">78</xref></sup> The functional relationship between the NK1 receptor and the serotonergic system was also demonstrated by studies on NK1 knock-out mice. The constitutive lack of NK1 receptors appeared to be associated with a downregulation and functional desensitization of 5-HT<sub>1a</sub> autoreceptors. The serotonin receptor subtype la has been suggested to be critically involved in antidepressant action of selective serotonin-reuptake inhibitors (SSRIs) and its downregulation and desensitization in NK1 knock-out mice is equivalent to the effect of chronic treatment with SSRT antidepressants.<sup><xref ref-type="bibr" rid="ref79">79</xref></sup> Studies using NK1 receptor antagonists are not the only ones to show the anxiolytic and antidepressant potency of antagonizing the tachykinin receptors. The selective blockade of the NK2 receptor also exhibited the potency of antidepressant-like action. A recently published study demonstrated the positive effect of the NK2 receptor antagonist SR48968 on the mobility in the forced swimming test in mice and rats, and on the maternal separation-induced vocalizations in guineapig pups. This behavioral effect was associated with a reduced separation-induced increase in the number of neurons displaying NK1 receptor internalization in the amygdala.<sup><xref ref-type="bibr" rid="ref80">80</xref></sup> In contrast, the NK3 receptor seems to play a differential role in depression-like behavior: another recent study using the forced swimming test as mousemodel of depression showed the positive effect of the NK3 receptor agonist aminosenktide. Stimulation of the NK3 receptor shortened the time of immobility to the same extent as the prototypic antidepressant desipramine in two out of three investigated mouse lines.<sup><xref ref-type="bibr" rid="ref81">81</xref></sup> The anxiolytic effect of NK3 receptor agonists had already been shown by the elevated plus-maze test.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> These antidepressant-like and anxiolytic potencies of NK3 agonist properties may be related to the activation of the endogenous opioid system through NK3 receptor stimulation, as shown previously.<sup><xref ref-type="bibr" rid="ref82">82</xref></sup>
</p></sec><sec><title>Clinical pharmacological studies on neurokinin receptor antagonists</title><p>In 1998, Mark Kramer and colleagues published the first report of a clinical study testing the antidepressant efficacy of an NK1 receptor antagonist.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> This randomized, double-blind, placebo-controlled and active (paroxetine)-controlled study investigated the safety and efficacy of MK869, a selective NK1 receptor antagonist. This study has been subject of several more or less extensive reviews and commentaries,<sup><xref ref-type="bibr" rid="ref73">73</xref>,<xref ref-type="bibr" rid="ref83">83</xref>-<xref ref-type="bibr" rid="ref85">85</xref></sup> and so we will just give a short overview of the most important findings here. Outpatients with major depressive disorder and moderately high anxiety levels received a single daily dose of 300 mg MK869 (n=66), 20 mg paroxetine (n=68), or a placebo (n=64) for 6 weeks in four different study centers. Efficacy measurements were made at the end of weeks 1, 2, 4, and 6 by the Hamilton Depression scale total score (HAM-D21) and the Clinical Global Impressions Severity (CGI-S) scale. The principal outcome was a 4.3-point difference between MK869 and placebo on the HAM-D21 score, confirming the antidepressant efficacy of M.K869. This NK1 receptor antagonist also demonstrated significant anxiolytic efficacy in the depressed patients. MK869 was well tolerated and, notably, the incidence of sexual dysfunction was 23% lower than in patients receiving paroxetine. These data encouraged the researchers to conduct a large dose-finding study of the same compound in patients with major depression, but the findings of this second study were not definitive due to the high placebo response rate.<sup><xref ref-type="bibr" rid="ref86">86</xref></sup>
</p><p>Despite this sobering result, these workers continued to prove the concept of NK1 receptor antagonism as a treatment strategy in major depression and carried out a clinical study with a second, more potent NK1 receptor antagonist, wich they called &#x0201c;compound A.&#x0201d; Outpatients with a diagnosis of major depression with melancholic features received either a daily dose of compound A (n=66) or a placebo (n=62) for 6 weeks in a randomized, double-blind, placebo-controlled study. The results were presented at the 2001 annual American College of Neuropsychopharmacology (ACNP) meeting.<sup><xref ref-type="bibr" rid="ref87">87</xref></sup> The mean decrease from baseline in HAM-D17 total score was 10.7 points in the verum group, whereas the placebo group exhibited an improvement of 7.8 points. Statistical analysis showed that this difference of 2.9 points reflected a significantly more pronounced improvement in patients who received compound A (<italic>P</italic>&#x0003c;0.009). Mean scores on the CGI-I scale also improved significantly in favor of compound A (<italic>P</italic>&#x0003c;0.009). Compound A appeared to be safe and well tolerated. The indices for sexual side effects and gastrointestinal symptoms were similar to those observed in the placebo group. The authors concluded that SP antagonism is a generally well-tolerated antidepressant mechanism.<sup><xref ref-type="bibr" rid="ref87">87</xref></sup>
</p><p>A third NK1 receptor antagonist, NKP608, is currently in phase 2 clinical trials as an antidepressant drug, but no data have been published on its efficacy to date.</p></sec><sec><title>Aspects for the future</title><p>Our results indicate the possible influence of a functional polymorphism within the ACE. gene on the therapeutic outcome in affective disorders.<sup><xref ref-type="bibr" rid="ref88">88</xref></sup> As stated above, ACE] is one of the SP-degrading enzymes. About 50% of the interindividual ACE] concentration is determined by an insertion/deletion polymorphism of the ACE. gene,<sup><xref ref-type="bibr" rid="ref89">89</xref></sup> with the D-allele being associated with higher ACE levels<sup><xref ref-type="bibr" rid="ref90">90</xref></sup> and increased neuropeptide degradation.<sup><xref ref-type="bibr" rid="ref91">91</xref></sup> Our findings in patients with major depression demonstrate that D-allele carriers show markedly lower scores on the Hamilton depression scale, remitted more often, and had a shorter duration of hospitalization. This relationship between the genotype of the SP-degrading enzyme and both severity of depression and treatment response suggests the potential role of SP in the pathophysiology of major depression. Genotyping of this ACE] polymorphism might help to identify those patients with major depression, who are predisposed to NK1 receptor antagonists.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>A.</given-names></name></person-group><article-title>A paradigm shift in brain research.</article-title><source><italic>Science.</italic></source><year>2001</year><volume>294</volume><fpage>1021</fpage><lpage>1024</lpage><pub-id pub-id-type="pmid">11691978</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>MS.</given-names></name><name><surname>Cutler</surname><given-names>N.</given-names></name><name><surname>Feighner</surname><given-names>J.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Distinct mechanism for antidepressant activity by blockade of central substance P receptors.</article-title><source><italic>Science.</italic></source><year>1998</year><volume>281</volume><fpage>1640</fpage><lpage>1645</lpage><pub-id pub-id-type="pmid">9733503</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Euler</surname><given-names>US.</given-names></name><name><surname>Gaddum</surname><given-names>JH.</given-names></name></person-group><article-title>An unidentified depressor substance in certain tissue extracts.</article-title><source><italic>J Physiol Land.</italic></source><year>1931</year><volume>72</volume><fpage>74</fpage><lpage>87</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lembeck</surname><given-names>F.</given-names></name></person-group><article-title>Zur Frage der zentralen Obertragung afferenter Impulse III. Mitteilung. Das Vorkommen und die Bedeutung der Substanz P in den dorsalen Wurzeln des R&#x000fc;ckenmarks.</article-title><source><italic>Naunyn Schmiedebergs Arch Pharmacol.</italic></source><year>1953</year><volume>219</volume><fpage>197</fpage><lpage>213</lpage></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>MM.</given-names></name><name><surname>Leeman</surname><given-names>SE.</given-names></name><name><surname>Niall</surname><given-names>HD.</given-names></name></person-group><article-title>Amino-acid sequence of substance P.</article-title><source><italic>Nat New Biol.</italic></source><year>1971</year><volume>232</volume><fpage>86</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">5285346</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantyh</surname><given-names>PW.</given-names></name><name><surname>Maggio</surname><given-names>JE.</given-names></name><name><surname>Hunt</surname><given-names>SP.</given-names></name></person-group><article-title>The autoradiographic distribution of kassinin and substance K binding sites is different from the distribution of substance P binding sites in rat brain.</article-title><source><italic>Eur J Pharmacol.</italic></source><year>1984</year><volume>102</volume><fpage>361</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">6090164</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanazawa</surname><given-names>I.</given-names></name><name><surname>Ogawa</surname><given-names>T.</given-names></name><name><surname>Kimura</surname><given-names>S.</given-names></name><name><surname>Munekata</surname><given-names>E.</given-names></name></person-group><article-title>Regional distribution of substance P, neurokinin alpha and neurokinin beta in rat central nervous system.</article-title><source><italic>Neurosci Res.</italic></source><year>1984</year><volume>2</volume><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">6085650</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>S.</given-names></name><name><surname>Goto</surname><given-names>K.</given-names></name><name><surname>Ogawa</surname><given-names>T.</given-names></name><name><surname>Sugita</surname><given-names>Y.</given-names></name><name><surname>Kanazawa</surname><given-names>I.</given-names></name></person-group><article-title>Pharmacological characterization of novel mammalian tachykinins, neurokinin alpha and neurokinin beta.</article-title><source><italic>Neurosci Res</italic></source><year>1984</year><volume>2</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">6085651</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strand</surname><given-names>FL.</given-names></name></person-group><source><italic>Neuropeptides: Regulators of Physiological Processes.</italic> 1st ed. Cambridge, Mass: The MIT Press;</source><year>1999</year></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>S.</given-names></name><name><surname>Sperk</surname><given-names>G.</given-names></name></person-group><article-title>Neurochemical characterization of preprotachykinin B(50-79) immunoreactivity in the rat.</article-title><source><italic>Regul Pept</italic></source><year>1995</year><volume>57</volume><fpage>183</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">7659792</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>JE.</given-names></name><name><surname>Chirgwin</surname><given-names>JM.</given-names></name><name><surname>Carter</surname><given-names>MS.</given-names></name><name><surname>Xu</surname><given-names>ZS.</given-names></name><name><surname>Hershey</surname><given-names>AD.</given-names></name></person-group><article-title>Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A.</article-title><source><italic>Proc Natl Acad Sci USA.</italic></source><year>1987</year><volume>84</volume><fpage>881</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">2433692</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiskerstrand</surname><given-names>C.</given-names></name><name><surname>Quinn</surname><given-names>JP.</given-names></name></person-group><article-title>The molecular biology of preprotachykinin-A gene expression.</article-title><source><italic>Neuropeptides.</italic></source><year>1996</year><volume>30</volume><fpage>602</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">9004259</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hokfelt</surname><given-names>T.</given-names></name><name><surname>Pernow</surname><given-names>B.</given-names></name><name><surname>Wahren</surname><given-names>J.</given-names></name></person-group><article-title>Substance P: a pioneer amongst neuropeptides.</article-title><source><italic>J Intern Med.</italic></source><year>2001</year><volume>249</volume><fpage>27</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">11168782</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LH.</given-names></name><name><surname>Ahmad</surname><given-names>S.</given-names></name><name><surname>Benter</surname><given-names>IF.</given-names></name><name><surname>Chow</surname><given-names>A.</given-names></name><name><surname>Mizutani</surname><given-names>S.</given-names></name><name><surname>Ward</surname><given-names>PE.</given-names></name></person-group><article-title>Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme.</article-title><source><italic>Peptides.</italic></source><year>1991</year><volume>12</volume><fpage>1357</fpage><lpage>1364</lpage><pub-id pub-id-type="pmid">1726123</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csuhai</surname><given-names>E.</given-names></name><name><surname>Little</surname><given-names>SS.</given-names></name><name><surname>Hersh</surname><given-names>LB.</given-names></name></person-group><article-title>Inactivation of neuropeptides.</article-title><source><italic>Prog Brain Res.</italic></source><year>1995</year><volume>104</volume><fpage>131</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">8552765</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>SM.</given-names></name></person-group><article-title>Peptides and psychiatry. Part 1. How synthesis of neuropeptides differs from classical neurotransmitter synthesis.</article-title><source><italic>J Clin Psychiatry</italic></source><year>1999</year><volume>60</volume><fpage>5</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10074870</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YQ.</given-names></name><name><surname>Wang</surname><given-names>ZM.</given-names></name><name><surname>Zheng</surname><given-names>HX.</given-names></name><name><surname>Shi</surname><given-names>JW.</given-names></name></person-group><article-title>Central origins of substance P-like immunoreactive fibers and terminals in the spinal trigeminal caudal subnucleus in the rat.</article-title><source><italic>Brain Res.</italic></source><year>1996</year><volume>719</volume><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">8782885</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chawla</surname><given-names>MK.</given-names></name><name><surname>Gutierrez</surname><given-names>GM.</given-names></name><name><surname>Young</surname><given-names>WS III.</given-names></name><name><surname>McMullen</surname><given-names>NT.</given-names></name><name><surname>Rance</surname><given-names>NE.</given-names></name></person-group><article-title>Localization of neurons expressing substance P and neurokinin B gene transcripts in the human hypothalamus and basal forebrain.</article-title><source><italic>J Comp Neurol.</italic></source><year>1997</year><volume>384</volume><fpage>429</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">9254037</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>PE.</given-names></name><name><surname>Fernstrom</surname><given-names>MH.</given-names></name><name><surname>Rorstad</surname><given-names>OP.</given-names></name><name><surname>Leeman</surname><given-names>SE.</given-names></name><name><surname>Martin</surname><given-names>JB.</given-names></name></person-group><article-title>The regional distribution of somatostatin, substance P and neurotensin in human brain.</article-title><source><italic>Brain Res.</italic></source><year>1981</year><volume>218</volume><fpage>219</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">6168327</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hokfelt</surname><given-names>T.</given-names></name><name><surname>Reid</surname><given-names>M.</given-names></name><name><surname>Herrera-Marschitz</surname><given-names>M.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Tachykinins and related peptides in the substantia nigra and neostriatum.</article-title><source><italic>Ann N Y Acad Sci.</italic></source><year>1991</year><volume>632</volume><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">1719865</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>LR.</given-names></name><name><surname>Harlan</surname><given-names>RE.</given-names></name></person-group><article-title>Cholinergic regulation of tachykinin- and enkephalin-gene expression in the rat striatum.</article-title><source><italic>Brain Res Mol Brain Res.</italic></source><year>1995</year><volume>30</volume><fpage>181</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">7637570</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>KG.</given-names></name><name><surname>Halliday</surname><given-names>GM.</given-names></name><name><surname>Hornung</surname><given-names>JP.</given-names></name><name><surname>Geffen</surname><given-names>LB.</given-names></name><name><surname>Cotton</surname><given-names>RG.</given-names></name><name><surname>Tork</surname><given-names>I.</given-names></name></person-group><article-title>Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus.</article-title><source><italic>Neuroscience.</italic></source><year>1991</year><volume>42</volume><fpage>757</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">1720227</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sergeyev</surname><given-names>V.</given-names></name><name><surname>Hokfelt</surname><given-names>T.</given-names></name><name><surname>Hurd</surname><given-names>Y.</given-names></name></person-group><article-title>Serotonin and substance P co-exist in dorsal raphe neurons of the human brain.</article-title><source><italic>Neuroreport.</italic></source><year>1999</year><volume>10</volume><fpage>3967</fpage><lpage>3970</lpage><pub-id pub-id-type="pmid">10716242</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvidsson</surname><given-names>U.</given-names></name><name><surname>Cullheim</surname><given-names>S.</given-names></name><name><surname>Ulfhake</surname><given-names>B.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Quantitative and qualitative aspects on the distribution of 5-HT and its coexistence with substance P and TRH in cat ventral medullary neurons.</article-title><source><italic>J Chem Neuroanat</italic></source><year>1994</year><volume>7</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">7528511</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>JN.</given-names></name><name><surname>Manaker</surname><given-names>S.</given-names></name></person-group><article-title>Colocalization of substance P or enkephalin rotonergic neuronal aff&#x000e9;rents to the hypoglossal nucleus in the rat.</article-title><source><italic>J Comp Neurol.</italic></source><year>1998</year><volume>391</volume><fpage>491</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">9486827</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>RP.</given-names></name><name><surname>Dorsa</surname><given-names>DM.</given-names></name></person-group><article-title>Colocalization of serotonin receptor subtypes 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, and 5-HT<sub>6</sub> with neuropeptides in rat striatum.</article-title><source><italic>J Comp Neurol.</italic></source><year>96</year><volume>370</volume><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">8799865</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirayama</surname><given-names>Y.</given-names></name><name><surname>Mitsushio</surname><given-names>H.</given-names></name><name><surname>Takashima</surname><given-names>M.</given-names></name><name><surname>Ichikawa</surname><given-names>H.</given-names></name><name><surname>Takahashi</surname><given-names>K.</given-names></name></person-group><article-title>Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat.</article-title><source><italic>Brain Res.</italic></source><year>1996</year><volume>739</volume><fpage>70</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">8955926</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>MK.</given-names></name><name><surname>Bannon</surname><given-names>MJ.</given-names></name></person-group><article-title>Tachykinin NKl receptor antagonists enhance stress-induced c-fos in rat locus coeruleus.</article-title><source><italic>Eur J Pharmacol.</italic></source><year>1998</year><volume>348</volume><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">9652329</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheeseman</surname><given-names>HJ.</given-names></name><name><surname>Pinnock</surname><given-names>RD.</given-names></name><name><surname>Henderson</surname><given-names>G.</given-names></name></person-group><article-title>Substance P excitation of rat locus coeruleus neurones.</article-title><source><italic>Eur J Pharmacol.</italic></source><year>1983</year><volume>94</volume><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">6197310</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guyenet</surname><given-names>PG.</given-names></name><name><surname>Aghajanian</surname><given-names>GK.</given-names></name></person-group><article-title>Excitation of neurons in the nucleus locus coeruleus by substance P and related peptides.</article-title><source><italic>Brain Res.</italic></source><year>1977</year><volume>136</volume><fpage>178</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">412562</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLean</surname><given-names>S.</given-names></name><name><surname>Ganong</surname><given-names>AH.</given-names></name><name><surname>Seeger</surname><given-names>TF.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist.</article-title><source><italic>Science.</italic></source><year>1991</year><volume>251</volume><fpage>437</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">1703324</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickel</surname><given-names>VM.</given-names></name><name><surname>Joh</surname><given-names>TH.</given-names></name><name><surname>Chan</surname><given-names>J.</given-names></name></person-group><article-title>Substance P in the rat nucleus accumbens: ultrastructural localization in axon terminals and their relation to dopaminergic afferents.</article-title><source><italic>Brain Res.</italic></source><year>1988</year><volume>444</volume><fpage>247</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">2451997</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Moine</surname><given-names>C.</given-names></name><name><surname>Normand</surname><given-names>E.</given-names></name><name><surname>Bloch</surname><given-names>B.</given-names></name></person-group><article-title>Phenotypical characterization of the rat striatal neurons expressing the D, dopamine receptor gene.</article-title><source><italic>Proc Natl Acad Sci U S A.</italic></source><year>1991</year><volume>88</volume><fpage>4205</fpage><lpage>4209</lpage><pub-id pub-id-type="pmid">1827915</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaber</surname><given-names>M.</given-names></name><name><surname>Normand</surname><given-names>E.</given-names></name><name><surname>Bloch</surname><given-names>B.</given-names></name></person-group><article-title>Effect of reserpine treatment on enkephalin mRNA level in the rat striatum: an in situ hybridization study.</article-title><source><italic>Brain Res Mol Brain Res.</italic></source><year>1995</year><volume>32</volume><fpage>156</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">7494455</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altier</surname><given-names>N.</given-names></name><name><surname>Stewart</surname><given-names>J.</given-names></name></person-group><article-title>The role of dopamine in the nucleus accumbens in analgesia.</article-title><source><italic>Life Sci.</italic></source><year>1999</year><volume>65</volume><fpage>2269</fpage><lpage>2287</lpage><pub-id pub-id-type="pmid">10597883</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dufourny</surname><given-names>L.</given-names></name><name><surname>Warembourg</surname><given-names>M.</given-names></name><name><surname>Jolivet</surname><given-names>A.</given-names></name></person-group><article-title>Quantitative studies of progesterone receptor and nitric oxide synthase colocalization with somatostatin, or neurotensin, or substance P in neurons of the guinea pig ventrolateral hypothalamic nucleus: an immunocytochemical triple-label analysis.</article-title><source><italic>J Chem Neuroanat</italic></source><year>1999</year><volume>17</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">10569238</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saria</surname><given-names>A.</given-names></name></person-group><article-title>The tachykinin NK1 receptor in the brain: pharmacology and putative functions.</article-title><source><italic>Eur J Pharmacol</italic></source><year>1999</year><volume>375</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">10443564</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>LF.</given-names></name><name><surname>Haskell</surname><given-names>CA.</given-names></name><name><surname>Hanley</surname><given-names>MR.</given-names></name></person-group><article-title>Functional characterization by heterologous expression of a novel cloned tachykinin peptide receptor.</article-title><source><italic>Biochem J.</italic></source><year>1996</year><volume>320</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8947459</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarau</surname><given-names>HM.</given-names></name><name><surname>Mooney</surname><given-names>JL.</given-names></name><name><surname>Schmidt</surname><given-names>DB.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Evidence that the proposed novel human &#x0201c;neurokinin-4&#x0201d; receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human origin.</article-title><source><italic>Mol Pharmacol.</italic></source><year>2000</year><volume>58</volume><fpage>552</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">10953048</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maggi</surname><given-names>CA.</given-names></name><name><surname>Schwartz</surname><given-names>TW.</given-names></name></person-group><article-title>The dual nature of the tachykinin NK1 receptor.</article-title><source><italic>Trends Pharmacol Sci.</italic></source><year>1997</year><volume>18</volume><fpage>351</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">9357319</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerard</surname><given-names>NP.</given-names></name><name><surname>Garraway</surname><given-names>LA.</given-names></name><name><surname>Eddy</surname><given-names>RL Jr.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones.</article-title><source><italic>Biochemistry</italic></source><year>1991</year><volume>30</volume><fpage>10640</fpage><lpage>10646</lpage><pub-id pub-id-type="pmid">1657150</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohm</surname><given-names>SK.</given-names></name><name><surname>Grady</surname><given-names>EF.</given-names></name><name><surname>Bunnett</surname><given-names>NW.</given-names></name></person-group><article-title>Regulatory mechanisms that modulate signalling by G-protein-coupled receptors.</article-title><source><italic>Biochem J.</italic></source><year>1997</year><volume>322</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">9078236</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>MA.</given-names></name><name><surname>LeVine</surname><given-names>H III.</given-names></name></person-group><article-title>Desensitization of the neurokinin 1 receptor is mediated by the receptor carboxy-terminal region, but is not caused by receptor internalization.</article-title><source><italic>J Neurochem.</italic></source><year>1996</year><volume>67</volume><fpage>2362</fpage><lpage>2372</lpage><pub-id pub-id-type="pmid">8931468</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garland</surname><given-names>AM.</given-names></name><name><surname>Grady</surname><given-names>EF.</given-names></name><name><surname>Lovett</surname><given-names>M.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Mechanisms of desensitization and resensitization of G protein-coupled neurokinin! and neurokinin2 receptors.</article-title><source><italic>Mol Pharmacol.</italic></source><year>1996</year><volume>49</volume><fpage>438</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">8643083</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quartara</surname><given-names>L.</given-names></name><name><surname>Maggi</surname><given-names>CA.</given-names></name></person-group><article-title>The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation.</article-title><source><italic>Neuropeptides.</italic></source><year>1997</year><volume>31</volume><fpage>537</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">9574822</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>M.</given-names></name><name><surname>Yoshioka</surname><given-names>K.</given-names></name></person-group><article-title>Neurotransmitter functions of mammalian tachykinins.</article-title><source><italic>Physiol Rev.</italic></source><year>1993</year><volume>73</volume><fpage>229</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">7682720</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LW.</given-names></name><name><surname>Wei</surname><given-names>LC.</given-names></name><name><surname>Liu</surname><given-names>HL.</given-names></name><name><surname>Rao</surname><given-names>ZR.</given-names></name></person-group><article-title>Noradrenergic neurons expressing substance P receptor (NK1) in the locus coeruleus complex: a double immunofluorescence study in the rat.</article-title><source><italic>Brain Res.</italic></source><year>2000</year><volume>873</volume><fpage>155</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">10915824</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannon</surname><given-names>MJ.</given-names></name><name><surname>Whitty</surname><given-names>CJ.</given-names></name></person-group><article-title>Neurokinin receptor gene expression in substantia nigra: localization, regulation, and potential physiological significance.</article-title><source><italic>Can J Physiol Pharmacol.</italic></source><year>1995</year><volume>73</volume><fpage>866</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">8846423</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>LF.</given-names></name><name><surname>Haskell</surname><given-names>CA.</given-names></name><name><surname>Hanley</surname><given-names>MR.</given-names></name></person-group><article-title>Messenger RNA localization and further characterisation of the putative tachykinin receptor NK4 (NK3B).</article-title><source><italic>Receptors Channels.</italic></source><year>2001</year><volume>7</volume><fpage>259</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">11697232</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Kaneko</surname><given-names>T.</given-names></name><name><surname>Mizuno</surname><given-names>N.</given-names></name></person-group><article-title>Colocalization of neuronal nitric oxide synthase and neurokinin-1 receptor in striatal interneurons in the rat.</article-title><source><italic>Neurosci Lett.</italic></source><year>2001</year><volume>310</volume><fpage>109</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">11585579</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>PJ.</given-names></name><name><surname>Iversen</surname><given-names>SD.</given-names></name></person-group><article-title>Behavioural effects of tachykinins and related peptides.</article-title><source><italic>Brain Res.</italic></source><year>1986</year><volume>381</volume><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">2428433</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname><given-names>LJ.</given-names></name><name><surname>Young</surname><given-names>L.</given-names></name></person-group><article-title>Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils.</article-title><source><italic>Eur J Pharmacol</italic></source><year>1994</year><volume>253</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">7515350</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krase</surname><given-names>W.</given-names></name><name><surname>Koch</surname><given-names>M.</given-names></name><name><surname>Schnitzler</surname><given-names>HU.</given-names></name></person-group><article-title>Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats.</article-title><source><italic>Behav Brain Res.</italic></source><year>1994</year><volume>63</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">7524534</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>PJ.</given-names></name></person-group><article-title>Place aversion induced by the substance P analogue, dimethyl-C7, is not state dependent: implication of substance P in aversion.</article-title><source><italic>Exp Brain Res.</italic></source><year>1988</year><volume>73</volume><fpage>354</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">2463935</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>RM.</given-names></name><name><surname>Santos</surname><given-names>AR.</given-names></name><name><surname>Ribeiro</surname><given-names>SJ.</given-names></name><name><surname>Calixto</surname><given-names>JB.</given-names></name><name><surname>Rae</surname><given-names>GA.</given-names></name><name><surname>De Lima</surname><given-names>TC.</given-names></name></person-group><article-title>Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice.</article-title><source><italic>Eur J Pharmacol.</italic></source><year>1996</year><volume>311</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">8884230</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>SJ.</given-names></name><name><surname>Teixeira</surname><given-names>RM.</given-names></name><name><surname>Calixto</surname><given-names>JB.</given-names></name><name><surname>De Lima</surname><given-names>TC.</given-names></name></person-group><article-title>Tachykinin NK(3)receptor involvement in anxiety.</article-title><source><italic>Neuropeptides</italic></source><year>1999</year><volume>33</volume><fpage>181</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">10657489</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguiar</surname><given-names>MS.</given-names></name><name><surname>Brandao</surname><given-names>ML.</given-names></name></person-group><article-title>Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test.</article-title><source><italic>Physiol Behav.</italic></source><year>1996</year><volume>60</volume><fpage>1183</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">8884951</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasenohrl</surname><given-names>RU.</given-names></name><name><surname>Jentjens</surname><given-names>O.</given-names></name><name><surname>Souza Silva</surname><given-names>MA.</given-names></name><name><surname>Tornaz</surname><given-names>C.</given-names></name><name><surname>Huston</surname><given-names>JP.</given-names></name></person-group><article-title>Anxiolytic-like action of neurokinin substance P administered systemically or into the nucleus basalis magnocellularis region.</article-title><source><italic>Eur J Pharmacol.</italic></source><year>1998</year><volume>354</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">9754912</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santarelli</surname><given-names>L.</given-names></name><name><surname>Gobbi</surname><given-names>G.</given-names></name><name><surname>Debs</surname><given-names>PC.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function.</article-title><source><italic>Proc Natl Acad Sci USA.</italic></source><year>2001</year><volume>98</volume><fpage>1912</fpage><lpage>1917</lpage><pub-id pub-id-type="pmid">11172050</pub-id></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Felipe</surname><given-names>C.</given-names></name><name><surname>Herrero</surname><given-names>JF.</given-names></name><name><surname>O'Brien</surname><given-names>JA.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Altered nociception, analgesia and aggression in mice lacking the receptor for substance P.</article-title><source><italic>Nature.</italic></source><year>1998</year><volume>392</volume><fpage>394</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">9537323</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>A.</given-names></name><name><surname>Schubert</surname><given-names>KL.</given-names></name><name><surname>Shaikh</surname><given-names>MB.</given-names></name></person-group><article-title>Neurotransmitters regulating defensive rage behavior in the cat.</article-title><source><italic>Neurosci Biobehav Rev.</italic></source><year>1997</year><volume>21</volume><fpage>733</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">9415898</pub-id></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaikh</surname><given-names>MB.</given-names></name><name><surname>Steinberg</surname><given-names>A.</given-names></name><name><surname>Siegel</surname><given-names>A.</given-names></name></person-group><article-title>Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat.</article-title><source><italic>Brain Res.</italic></source><year>1993</year><volume>625</volume><fpage>283</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">7506110</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubinsky</surname><given-names>B.</given-names></name><name><surname>Goldberg</surname><given-names>ME.</given-names></name></person-group><article-title>The effect of imipramine and selected drugs on attack elicited by hypothalamic stimulation in the cat.</article-title><source><italic>Neuropharmacology</italic></source><year>1971</year><volume>10</volume><fpage>537</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">5166620</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCluskey</surname><given-names>LP.</given-names></name><name><surname>Lampson</surname><given-names>LA.</given-names></name></person-group><article-title>Local immune regulation in the central nervous system by substance P vs glutamate.</article-title><source><italic>J Neuroimmunol.</italic></source><year>2001</year><volume>116</volume><fpage>136</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">11438168</pub-id></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000e9;vite</surname><given-names>M.</given-names></name></person-group><article-title>Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype.</article-title><source><italic>Proc Natl Acad Sci U S A.</italic></source><year>1998</year><volume>95</volume><fpage>12544</fpage><lpage>12549</lpage><pub-id pub-id-type="pmid">9770522</pub-id></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>MJ.</given-names></name><name><surname>Chiang</surname><given-names>S.</given-names></name><name><surname>MCiller</surname><given-names>N.</given-names></name><name><surname>Ackenheil</surname><given-names>M.</given-names></name></person-group><article-title>T-helper-1 and T-helper2 responses in psychiatric disorders.</article-title><source><italic>Brain Behav Irnrnun.</italic></source><year>2001</year><volume>15</volume><fpage>340</fpage><lpage>370</lpage></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folkers</surname><given-names>K.</given-names></name><name><surname>Horig</surname><given-names>J.</given-names></name><name><surname>Resell</surname><given-names>S.</given-names></name><name><surname>Bjorkroth</surname><given-names>U.</given-names></name></person-group><article-title>Chemical design of antagonists of substance P.</article-title><source><italic>Acta Physiol Scand</italic></source><year>1981</year><volume>111</volume><fpage>505</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">6171138</pub-id></element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snider</surname><given-names>RM.</given-names></name><name><surname>Constantine</surname><given-names>JW.</given-names></name><name><surname>Lowe</surname><given-names>JA III.</given-names></name><name><surname>et al</surname></name></person-group><article-title>A potent nonpeptide antagonist of the substance P (NK1) receptor.</article-title><source><italic>Science.</italic></source><year>1991</year><volume>251</volume><fpage>435</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">1703323</pub-id></element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gether</surname><given-names>U.</given-names></name><name><surname>Johansen</surname><given-names>TE.</given-names></name><name><surname>Snider</surname><given-names>RM.</given-names></name><name><surname>Lowe</surname><given-names>JA III.</given-names></name><name><surname>Nakanishi</surname><given-names>S.</given-names></name><name><surname>Schwartz</surname><given-names>TW.</given-names></name></person-group><article-title>Different binding epitopes on the NKl receptor for substance P and non-peptide antagonist.</article-title><source><italic>Nature.</italic></source><year>1993</year><volume>362</volume><fpage>345</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">7681152</pub-id></element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radhakrishnan</surname><given-names>V.</given-names></name><name><surname>Iyengar</surname><given-names>S.</given-names></name><name><surname>Henry</surname><given-names>JL.</given-names></name></person-group><article-title>The nonpeptide NK-1 receptor antagonists LY303870 and LY306740 block the responses of spinal dorsal horn neurons to substance P and to peripheral noxious stimuli.</article-title><source><italic>Neuroscience.</italic></source><year>1998</year><volume>83</volume><fpage>1251</fpage><lpage>1260</lpage><pub-id pub-id-type="pmid">9502263</pub-id></element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>IJ.</given-names></name></person-group><article-title>Neurochemical pathogenesis of fibromyalgia syndrome.</article-title><source><italic>J Musculoskeletal Pain.</italic></source><year>1996</year><volume>4</volume><fpage>61</fpage><lpage>92</lpage></element-citation></ref><ref id="ref72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>MJ.</given-names></name><name><surname>Spaeth</surname><given-names>M.</given-names></name><name><surname>M&#x000fc;ller-Bardorff</surname><given-names>H.</given-names></name><name><surname>Pongratz</surname><given-names>D.</given-names></name><name><surname>Bondy</surname><given-names>B.</given-names></name><name><surname>Ackenheil</surname><given-names>M.</given-names></name></person-group><article-title>Relationship of substance P, 5-hydroxyindoleacetic acid and tryptophan in serum of fibromyalgia patients.</article-title><source><italic>Neurosci Lett.</italic></source><year>1999</year><volume>259</volume><fpage>196</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">10025591</pub-id></element-citation></ref><ref id="ref73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupniak</surname><given-names>NM.</given-names></name><name><surname>Kramer</surname><given-names>MS.</given-names></name></person-group><article-title>Discovery of the antidepressant and antiemetic efficacy of substance P receptor (NK1) antagonists.</article-title><source><italic>Trends Pharmacol Sci.</italic></source><year>1999</year><volume>20</volume><fpage>485</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">10671176</pub-id></element-citation></ref><ref id="ref74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupniak</surname><given-names>NM.</given-names></name><name><surname>Carlson</surname><given-names>EC.</given-names></name><name><surname>Harrison</surname><given-names>T.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice.</article-title><source><italic>Neuropharmacology</italic></source><year>2000</year><volume>39</volume><fpage>1413</fpage><lpage>1421</lpage><pub-id pub-id-type="pmid">10818257</pub-id></element-citation></ref><ref id="ref75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papp</surname><given-names>M.</given-names></name><name><surname>Vassout</surname><given-names>A.</given-names></name><name><surname>Gentsch</surname><given-names>C.</given-names></name></person-group><article-title>The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats.</article-title><source><italic>Behav Brain Res.</italic></source><year>2000</year><volume>115</volume><fpage>19</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">10996404</pub-id></element-citation></ref><ref id="ref76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>File</surname><given-names>SE.</given-names></name></person-group><article-title>NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats.</article-title><source><italic>Psychopharmacology (Bed).</italic></source><year>2000</year><volume>152</volume><fpage>105</fpage><lpage>109</lpage></element-citation></ref><ref id="ref77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyce</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><name><surname>Carlson</surname><given-names>E.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Intra-amygdala injection of the substance P [NK(1) receptor] antagonist L-760735 inhibits neonatal vocalisations in guinea-pigs.</article-title><source><italic>Neuropharmacology</italic></source><year>2001</year><volume>41</volume><fpage>130</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">11445193</pub-id></element-citation></ref><ref id="ref78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddjeri</surname><given-names>N.</given-names></name><name><surname>Blier</surname><given-names>P.</given-names></name></person-group><article-title>Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission.</article-title><source><italic>Biol Psychiatry</italic></source><year>2001</year><volume>50</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">11513818</pub-id></element-citation></ref><ref id="ref79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froger</surname><given-names>N.</given-names></name><name><surname>Gardier</surname><given-names>AM.</given-names></name><name><surname>Moratalla</surname><given-names>R.</given-names></name><name><surname>et al</surname></name></person-group><article-title>5-Hydroxytryptamine (5-HT)<sub>1A</sub> autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization.</article-title><source><italic>J Neurosci.</italic></source><year>2001</year><volume>21</volume><fpage>8188</fpage><lpage>8197</lpage><pub-id pub-id-type="pmid">11588191</pub-id></element-citation></ref><ref id="ref80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>R.</given-names></name><name><surname>Alonso</surname><given-names>R.</given-names></name><name><surname>Griebel</surname><given-names>G.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function.</article-title><source><italic>J Pharmacol Exp Ther.</italic></source><year>2001</year><volume>299</volume><fpage>449</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">11602654</pub-id></element-citation></ref><ref id="ref81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panocka</surname><given-names>I.</given-names></name><name><surname>Massi</surname><given-names>M.</given-names></name><name><surname>Lapo</surname><given-names>I.</given-names></name><name><surname>Swiderski</surname><given-names>T.</given-names></name><name><surname>Kowalczyk</surname><given-names>M.</given-names></name><name><surname>Sadowski</surname><given-names>B.</given-names></name></person-group><article-title>Antidepressant-type effect of the NK3 tachykinin receptor agonist aminosenktide in mouse lines differing in endogenous opioid system activity.</article-title><source><italic>Peptides.</italic></source><year>2001</year><volume>22</volume><fpage>1037</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">11445231</pub-id></element-citation></ref><ref id="ref82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>SJ.</given-names></name><name><surname>De Lima</surname><given-names>TC.</given-names></name></person-group><article-title>Naloxone-induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice.</article-title><source><italic>Neurosci Lett.</italic></source><year>1998</year><volume>258</volume><fpage>155</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">9885954</pub-id></element-citation></ref><ref id="ref83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nutt</surname><given-names>D.</given-names></name></person-group><article-title>Substance-P antagonists: a new treatment for depression?</article-title><source><italic>Lancet</italic></source><year>1998</year><volume>352</volume><fpage>1644</fpage><lpage>1646</lpage><pub-id pub-id-type="pmid">9853433</pub-id></element-citation></ref><ref id="ref84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argyropoulos</surname><given-names>SV.</given-names></name><name><surname>Nutt</surname><given-names>DJ.</given-names></name></person-group><article-title>Substance P antagonists: novel agents in the treatment of depression.</article-title><source><italic>Expert Opin Investig Drugs.</italic></source><year>2000</year><volume>9</volume><fpage>1871</fpage><lpage>1875</lpage></element-citation></ref><ref id="ref85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stout</surname><given-names>SC.</given-names></name><name><surname>Owens</surname><given-names>MJ.</given-names></name><name><surname>Nemeroff</surname><given-names>CB.</given-names></name></person-group><article-title>Neurokinin(1) receptor antagonists as potential antidepressants.</article-title><source><italic>Annu Rev Pharmacol Toxicol.</italic></source><year>2001</year><volume>41</volume><fpage>877</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">11264480</pub-id></element-citation></ref><ref id="ref86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>MS.</given-names></name></person-group><article-title>Update on Substance P (NK-1 receptor) antagonists in clinical trials for depression.</article-title><source><italic>Neuropeptides.</italic></source><year>2000</year><volume>34</volume><fpage>255</fpage><pub-id pub-id-type="pmid">11049729</pub-id></element-citation></ref><ref id="ref87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>MS.</given-names></name><name><surname>Ball</surname><given-names>WA.</given-names></name><name><surname>Reines</surname><given-names>SA.</given-names></name></person-group><article-title>Replication of the efficacy and tolerability of substance P antagonists in patients with major depression. American College of Neuropsychopharmacology (ACNP) 40th Anniversary Scientific Abstract Book. 2001. Abstract 128.</article-title></element-citation></ref><ref id="ref88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baghai</surname><given-names>T.</given-names></name><name><surname>Sch&#x000fc;le</surname><given-names>C.</given-names></name><name><surname>Zwanzger</surname><given-names>P.</given-names></name><name><surname>et al</surname></name></person-group><article-title>Possible influence of the insertion/deletion polymorphism in the angiotensin l-converting enzyme gene on therapeutic outcome in affective disorders.</article-title><source><italic>Moi Psychiatry</italic></source><year>2001</year><volume>6</volume><fpage>258</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">11326291</pub-id></element-citation></ref><ref id="ref89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigat</surname><given-names>B.</given-names></name><name><surname>Hubert</surname><given-names>C.</given-names></name><name><surname>Alhenc-Gelas</surname><given-names>F.</given-names></name><name><surname>Cambien</surname><given-names>F.</given-names></name><name><surname>Corvol</surname><given-names>P.</given-names></name><name><surname>Soubrier</surname><given-names>F.</given-names></name></person-group><article-title>An insertion/deletion polymorphism in the angiotensin l-converting enzyme gene accounting for half the variance of serum enzyme levels.</article-title><source><italic>J Clin invest</italic></source><year>1990</year><volume>86</volume><fpage>1343</fpage><lpage>1346</lpage><pub-id pub-id-type="pmid">1976655</pub-id></element-citation></ref><ref id="ref90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigat</surname><given-names>B.</given-names></name><name><surname>Hubert</surname><given-names>C.</given-names></name><name><surname>Corvol</surname><given-names>P.</given-names></name><name><surname>Soubrier</surname><given-names>F.</given-names></name></person-group><article-title>PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1).</article-title><source><italic>Nucleic Acids Res.</italic></source><year>1992</year><volume>20</volume><fpage>1433</fpage><pub-id pub-id-type="pmid">1313972</pub-id></element-citation></ref><ref id="ref91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphey</surname><given-names>LJ.</given-names></name><name><surname>Gainer</surname><given-names>JV.</given-names></name><name><surname>Vaughan</surname><given-names>DE.</given-names></name><name><surname>Brown</surname><given-names>NJ.</given-names></name></person-group><article-title>Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin.</article-title><source><italic>Circulation.</italic></source><year>2000</year><volume>102</volume><fpage>829</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">10952948</pub-id></element-citation></ref></ref-list><glossary><title>Selected abbreviations and acronyms</title><def-list id="DL1"><def-item><term>ACE</term><def><p>angiotensin-converting enzyme</p></def></def-item><def-item><term>FM</term><def><p>fibromyalgia syndrome</p></def></def-item><def-item><term>5-HT</term><def><p>5-hydroxytryptamine (serotonin)</p></def></def-item><def-item><term>ICV</term><def><p>intracerebroventricular</p></def></def-item><def-item><term>NE</term><def><p>norepinephrine</p></def></def-item><def-item><term>NKA</term><def><p>neurokinin A</p></def></def-item><def-item><term>NKB</term><def><p>neurokinin B</p></def></def-item><def-item><term>SP</term><def><p>substance P</p></def></def-item></def-list></glossary></back></article>